FOLH1 and cancer: The reported BiTEcan benefit from the much higher affinity of the 5D3 arm toward PSMA(as compared, for example, with the J591 antibody37), and its strict specificity can contribute to the enhancedsafety profile and ensure effective cancer cell eradication as a resultof direct contacts between the target and effector T-cells.75 At the same time, it is clear that further optimization/engineering,such as 5D3 humanization, might be needed to improve the translatabilityof the reported 5D3 into the clinic, and only clinical trials couldaddress its real-life scenario therapeutic potential.